SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
Ryan B. Corcoran(Massachusetts General Hospital), Aparna R. Parikh(Massachusetts General Hospital), Giulia Siravegna(University of Turin), Thomas A. Abrams(Dana-Farber Cancer Institute), Katie Kanter(Massachusetts General Hospital), Marios Giannakis(Broad Institute), Karin Pelka(Broad Institute), Nir Hacohen(Cambridge Hospital), Nadine J. McCleary(Harvard University), Andrea C. Enzinger(Harvard University), David P. Ryan(East Carolina University), Emily Van Seventer(Massachusetts General Hospital), Isobel J. Fetter(Harvard University), M. Yugelun(Harvard University), Jeffrey W. Clark(Massachusetts General Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Jinwei Tian(Harbin Medical University), J. Chen(Harvard University), Jill N. Allen(Harvard University), William B. Bradford(Harvard University), Serena H. Chao(Harvard University), Jeffrey A. Meyerhardt(CancerCare)
Cited by 43
Related Papers
Full-length transcriptome assembly from RNA-Seq data without a reference genome
|Nature Biotechnology|2011|22.7k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k